Bexarotene Patent Expiration
Bexarotene is Used for treating cutaneous lesions in patients with refractory or persistent stage IA and IB cutaneous T-cell lymphoma. It was first introduced by Bausch Health Ireland Ltd
Bexarotene Patents
Given below is the list of patents protecting Bexarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Targretin | US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct 05, 2016
(Expired) | Bausch |
| Targretin | US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul 14, 2015
(Expired) | Bausch |
Bexarotene's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Bexarotene:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | Stanford University | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1, PHASE2 |